Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-11T05:28:27.787Z Has data issue: false hasContentIssue false

Chapter 1 - An introduction to molecular pathology

Published online by Cambridge University Press:  05 November 2015

By
John M. S. Bartlett
Edited by
John M. S. Bartlett ,
Abeer Shaaban  and
Fernando Schmitt
John M. S. Bartlett
Affiliation:
Ontario Institute for Cancer Research, Toronto
Abeer Shaaban
Affiliation:
Queen Elizabeth Hospital Birmingham
Fernando Schmitt
Affiliation:
University of Porto
Get access
Type
Chapter
Information
Molecular Pathology
A Practical Guide for the Surgical Pathologist and Cytopathologist
 , pp. 1 - 9
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486(7403): 405–9.CrossRefGoogle ScholarPubMed
Grasso, C. S., Wu, Y. M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487(7406): 239–43.CrossRefGoogle ScholarPubMed
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van, L. P., Greenman, C. D., Raine, K. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149(5): 979–93.CrossRefGoogle ScholarPubMed
Nik-Zainal, S., Van, L. P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W. et al. The life history of 21 breast cancers. Cell 2012; 149(5): 994–1007.CrossRefGoogle ScholarPubMed
Stephens, P. J., Tarpey, P. S., Davies, H., Van, L. P., Greenman, C., Wedge, D. C. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486(7403): 400–4.CrossRefGoogle ScholarPubMed
Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72(19): 4875–82.CrossRefGoogle ScholarPubMed
Hudson, T. J., Anderson, W., Artez, A., Barker, A. D., Bell, C., Bernabe, R. R. et al. International network of cancer genome projects. Nature 2010; 464(7291): 993–8.Google ScholarPubMed
Pleasance, E. D. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463(7278): 184–90.CrossRefGoogle ScholarPubMed
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14(5): 1368–76.CrossRefGoogle ScholarPubMed
Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486(7403): 346–52.CrossRefGoogle Scholar
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 2012; 366(10): 883–92.CrossRefGoogle ScholarPubMed
Borresen-Dale, A. L., Hicks, J., Navin, N. and Russnes, H. G. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011; 121(10): 3810–18.Google Scholar
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J. et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472(7341): 90–4.CrossRefGoogle ScholarPubMed
Alayev, A. and Holz, M. K. mTOR signaling for biological control and cancer. J Cell Physiol 2013; 228(8): 1658–64.CrossRefGoogle ScholarPubMed
Banerjee, S. and Kaye, S. B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013; 19(5): 961–8.CrossRefGoogle ScholarPubMed
Rexer, B. N. and Arteaga, C. L. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res 2013; 73(13): 3817–20.CrossRefGoogle ScholarPubMed
Chen, K. G. and Sikic, B. I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012; 18(7): 1863–9.CrossRefGoogle ScholarPubMed
Dancey, J. E., Bedard, P. L., Onetto, N. and Hudson, T. J. The genetic basis for cancer treatment decisions. Cell 2012; 148(3): 409–20.CrossRefGoogle ScholarPubMed
Flaherty, K. T., Hodi, F. S. and Fisher, D. E. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12(5): 349–61.CrossRefGoogle ScholarPubMed
Kurtz, J. E. and Ray-Coquard, I. PI3 kinase inhibitors in the clinic: an update. Anticancer Res 2012; 32(7): 2463–70.Google ScholarPubMed
Wright, N. A. and Poulsom, R. Omnis cellula e cellula revisited: cell biology as the foundation of pathology. J Pathol 2012; 226(2): 145–7.CrossRefGoogle ScholarPubMed
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A. Jr., Franklin, W. A., Dziadziuszko, R., Thatcher, N. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31): 5034–42.CrossRefGoogle Scholar
Bell, R. What can we learn from Herceptin (R) trials in metastatic breast cancer? Oncology 2002; 63: 39–46.CrossRefGoogle Scholar
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of Pathology & Laboratory Medicine 2010; 134(7): E48–E72.CrossRefGoogle Scholar
Bartlett, J. M. S., Ibrahim, M., Jasani, B., Morgan, J. M., Ellis, I., Kay, E. et al. External quality assurance of HER2 FISH and ISH testing three years of the UK National External Quality Assurance Scheme. American J Clin Pathol 2009; 131(1): 106–11.CrossRefGoogle ScholarPubMed
Miller, K. D., Ibrahim, M., Barnett, S. and Jasani, B. Technical aspects of predictive and prognostic markers in breast cancer: What UK NEQAS data shows. Curr Diagn Pathol 2007; 13(2): 135–49.CrossRefGoogle Scholar
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118–45.CrossRefGoogle Scholar
Miller, K., Rhodes, A. and Jasani, B. Variation in rates of oestrogen receptor positivity in breast cancer again. BMJ 2002; 324(7332): 298–9.CrossRefGoogle Scholar
Rakha, E., Reis-Filho, J., Baehner, F., Dabbs, D., Decker, T., Eusebi, V. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 12(4): 207.CrossRefGoogle ScholarPubMed
Engers, R. Reproducibility and reliability of tumor grading in urological neoplasms. World J Urol 2007; 25(6): 595–605.CrossRefGoogle ScholarPubMed
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J. et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 2011; 103(22): 1656–64.CrossRefGoogle ScholarPubMed
Han, K., Nofech-Mozes, S., Narod, S., Hanna, W., Vesprini, D., Saskin, R. et al. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 2012; 24(3): 183–9.CrossRefGoogle ScholarPubMed
Sauter, G., Lee, J., Bartlett, J. M., Slamon, D. J. and Press, M. F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27(8): 1323–33.CrossRefGoogle ScholarPubMed
Dancey, J. E., Dobbin, K. K., Groshen, S., Jessup, J. M., Hruszkewycz, A. H., Koehler, M. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16(6): 1745–55.CrossRefGoogle ScholarPubMed
Simon, R. M., Paik, S. and Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101(21): 1446–52.CrossRefGoogle ScholarPubMed
Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C. and Gutman, S. I. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009; 101(21): 1453–63.CrossRefGoogle ScholarPubMed
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M. and Clark, G. M. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93(4): 387–91.CrossRefGoogle ScholarPubMed
Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H. et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687–717.Google Scholar
Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Nomura, Y. et al. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352(9132): 930–42.Google Scholar
Oxnard, G. R. and Jänne, P. A. Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 2013; 19(7): 1634–6.CrossRefGoogle ScholarPubMed
Schoenborn, J. R., Nelson, P. and Fang, M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res 2013; 19(15): 4058–66.CrossRefGoogle ScholarPubMed
Costello, E., Greenhalf, W. and Neoptolemos, J. P. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 2012; 9(8): 435–44.CrossRefGoogle ScholarPubMed
Ravdin, P. M. Adjuvant! version 5. Underlying data and assumptions. Breast Cancer Res Treat 2003; 82: 321.Google Scholar
Bartlett, J. M. S., Brookes, C. L., Robson, T., van de Velde, C. J. H., Billingham, L. J., Campbell, F. M. et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2011; 29(12): 1531–8.CrossRefGoogle ScholarPubMed
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011; 29(32): 4273–8.CrossRefGoogle ScholarPubMed
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004; 351(27): 2817–26.CrossRefGoogle ScholarPubMed
Hornberger, J., Alvarado, M. D., Rebecca, C., Gutierrez, H. R., Yu, T. M. and Gradishar, W. J. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104(14): 1068–79.CrossRefGoogle ScholarPubMed
Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379(9814): 432–44.Google Scholar
Hertel, P. B., Tu, D., Ejlertsen, B., Jensen, M. B., Balslev, E., Jiang, S. et al. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res Treat 2012; 132(1): 225–34.CrossRefGoogle ScholarPubMed
Pritchard, K., Munro, A., O'Malley, F., Tu, D., Li, X., Levine, M. et al. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat 2012; 131(2): 541–51.CrossRefGoogle Scholar
Di Leo, A., Isola, J., Piette, F., Ejlertsen, B., Pritchard, K. I., Bartlett, J. M. S. et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Res 2009; 69(2): 99S.CrossRefGoogle Scholar
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D. et al. HER2 and response to paclitaxel in node-positive breast cancer. New Engl J Med 2007; 357(15): 1496–506.CrossRefGoogle ScholarPubMed
Dowsett, M., Goldhirsch, A., Hayes, D. F., Senn, H. J., Wood, W. and Viale, G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007; 9(6): R81.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×